MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.3 -2.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.35

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+134.38% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-24M 79M
Предишно отваряне	4.29
Предишно затваряне	1.3

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.01.2026 г., 23:11 ч. UTC

Печалби

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7.01.2026 г., 22:55 ч. UTC

Значими двигатели на пазара

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7.01.2026 г., 21:39 ч. UTC

Значими двигатели на пазара

Raytheon Down Following Trump Post Criticizing Company

7.01.2026 г., 20:13 ч. UTC

Значими двигатели на пазара

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7.01.2026 г., 20:03 ч. UTC

Значими двигатели на пазара

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7.01.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7.01.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7.01.2026 г., 22:48 ч. UTC

Пазарно говорене

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7.01.2026 г., 22:46 ч. UTC

Печалби

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7.01.2026 г., 22:45 ч. UTC

Печалби

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Revolution Medicines Draws Takeover Interest -- 2nd Update

7.01.2026 г., 22:42 ч. UTC

Печалби

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7.01.2026 г., 22:41 ч. UTC

Печалби

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7.01.2026 г., 22:41 ч. UTC

Печалби

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7.01.2026 г., 22:40 ч. UTC

Значими двигатели на пазара

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7.01.2026 г., 22:31 ч. UTC

Пазарно говорене

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7.01.2026 г., 22:22 ч. UTC

Пазарно говорене

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7.01.2026 г., 22:01 ч. UTC

Пазарно говорене

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.01.2026 г., 21:46 ч. UTC

Пазарно говорене

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7.01.2026 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7.01.2026 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7.01.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7.01.2026 г., 20:29 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Near Deal for Revolution Medicines -- Update

7.01.2026 г., 20:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7.01.2026 г., 19:58 ч. UTC

Пазарно говорене

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7.01.2026 г., 19:48 ч. UTC

Значими двигатели на пазара

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

134.38% нагоре

12-месечна прогноза

Среден 3 USD 134.38%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.